Interestingly, overexpression of PD-1 induced exhaustion of activated CD8+ cells, and inhibition of PD-1 has been approved as a third-line therapy for advanced HCC in 2017 [111, 112]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.